Literature DB >> 30306781

Molecular underpinnings of enzalutamide resistance

S Prekovic1, T van den Broeck2,3, S Linder1, M E van Royen4,5, A B Houtsmuller4,5, F Handle2, S Joniau3, W Zwart1,6, F Claessens2.   

Abstract

Prostate cancer (PCa) is among the most common adult malignancies, and the second leading cause of cancer-related death in men. As PCa is hormone dependent, blockade of the androgen receptor (AR) signaling is an effective therapeutic strategy for men with advanced metastatic disease. The discovery of enzalutamide, a compound that effectively blocks the AR axis and its clinical application has led to a significant improvement in survival time. However, the effect of enzalutamide is not permanent, and resistance to treatment ultimately leads to development of lethal disease, for which there currently is no cure. This review will focus on the molecular underpinnings of enzalutamide resistance, bridging the gap between the preclinical and clinical research on novel therapeutic strategies for combating this lethal stage of prostate cancer. 2018 Society for Endocrinology

Entities:  

Keywords:  enzalutamide; abiraterone; resistance; androgen receptor; glycolysis; hexosamine biosynthesis; autophagy; cancer; prostate cancer; AKR3C1; Wnt; IL-6; mCRPC; mutations

Mesh：

Substances：

Year:  2018        PMID： 30306781     DOI： 10.1530/ERC-17-0136

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN： 1351-0088            Impact factor:   5.678


  10 in total

1.  A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer.

Authors:  Zhenyu Yang; Dan Wang; James K Johnson; Laura E Pascal; Keita Takubo; Raghunandan Avula; Anish Bhaswanth Chakka; Jianhua Zhou; Wei Chen; Mingming Zhong; Qiong Song; Hui Ding; Zeyu Wu; Uma R Chandran; Taber S Maskrey; Joel B Nelson; Peter Wipf; Zhou Wang
Journal:  Mol Cancer Ther       Date:  2019-09-25       Impact factor: 6.261

2.  Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.

Authors:  Simon Linder; Marlous Hoogstraat; Suzan Stelloo; Nils Eickhoff; Karianne Schuurman; Hilda de Barros; Maartje Alkemade; Elise M Bekers; Tesa M Severson; Joyce Sanders; Chia-Chi Flora Huang; Tunc Morova; Umut Berkay Altintas; Liesbeth Hoekman; Yongsoo Kim; Sylvan C Baca; Martin Sjöström; Anniek Zaalberg; Dorine C Hintzen; Jeroen de Jong; Roelof J C Kluin; Iris de Rink; Claudia Giambartolomei; Ji-Heui Seo; Bogdan Pasaniuc; Maarten Altelaar; René H Medema; Felix Y Feng; Amina Zoubeidi; Matthew L Freedman; Lodewyk F A Wessels; Lisa M Butler; Nathan A Lack; Henk van der Poel; Andries M Bergman; Wilbert Zwart
Journal:  Cancer Discov       Date:  2022-09-02       Impact factor: 38.272

3.  High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice.

Authors:  Riikka Huhtaniemi; Petra Sipilä; Arttu Junnila; Riikka Oksala; Matias Knuuttila; Arfa Mehmood; Eija Aho; Teemu D Laajala; Tero Aittokallio; Asta Laiho; Laura Elo; Claes Ohlsson; Malin Hagberg Thulin; Pekka Kallio; Sari Mäkelä; Mika V J Mustonen; Matti Poutanen
Journal:  iScience       Date:  2022-04-25

4.  Drivers of AR indifferent anti-androgen resistance in prostate cancer cells.

Authors:  Florian Handle; Stefan Prekovic; Christine Helsen; Thomas Van den Broeck; Elien Smeets; Lisa Moris; Roy Eerlings; Sarah El Kharraz; Alfonso Urbanucci; Ian G Mills; Steven Joniau; Gerhardt Attard; Frank Claessens
Journal:  Sci Rep       Date:  2019-09-24       Impact factor: 4.379

5.  TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

Authors:  Sander Al Palit; Daniel Vis; Suzan Stelloo; Cor Lieftink; Stefan Prekovic; Elise Bekers; Ingrid Hofland; Tonći Šuštić; Liesanne Wolters; Roderick Beijersbergen; Andries M Bergman; Balázs Győrffy; Lodewyk Fa Wessels; Wilbert Zwart; Michiel S van der Heijden
Journal:  Elife       Date:  2019-12-19       Impact factor: 8.140

6.  Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3'-diindolylmethane in an enzalutamide-resistant prostate cancer cell line.

Authors:  Chih-Wei Tsao; Jia-Sin Li; Ya-Wen Lin; Sheng-Tang Wu; Tai-Lung Cha; Chin-Yu Liu
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

7.  RNF8 up-regulates AR/ARV7 action to contribute to advanced prostate cancer progression.

Authors:  Tingting Zhou; Shengli Wang; Xiaoyu Song; Wensu Liu; Fang Dong; Yunlong Huo; Renlong Zou; Chunyu Wang; Siyi Zhang; Wei Liu; Ge Sun; Lin Lin; Kai Zeng; Xiang Dong; Qiqiang Guo; Fei Yi; Zhuo Wang; Xiaoman Li; Bo Jiang; Liu Cao; Yue Zhao
Journal:  Cell Death Dis       Date:  2022-04-15       Impact factor: 9.685

Review 8.  Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.

Authors:  Pravien Rajaram; Alyssa Rivera; Kevin Muthima; Nicholas Olveda; Hubert Muchalski; Qiao-Hong Chen
Journal:  Molecules       Date:  2020-05-24       Impact factor: 4.927

9.  Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond

Authors:  Simon Linder; Henk G van der Poel; Andries M Bergman; Wilbert Zwart; Stefan Prekovic
Journal:  Endocr Relat Cancer       Date:  2018-10-31       Impact factor: 5.678

10.  Upregulation of glucocorticoid receptor-mediated glucose transporter 4 in enzalutamide-resistant prostate cancer.

Authors:  Seiji Hoshi; Satoru Meguro; Hitomi Imai; Yuta Matsuoka; Yuki Yoshida; Akihumi Onagi; Ryo Tanji; Ruriko Honda-Takinami; Kanako Matsuoka; Tomoyuki Koguchi; Junya Hata; Yuichi Sato; Hidenori Akaihata; Masao Kataoka; Soichiro Ogawa; Yoshiyuki Kojima
Journal:  Cancer Sci       Date:  2021-03-11       Impact factor: 6.716
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.